NTLA logo

NTLA Intellia Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$10.00
+0.48 (+5.04%)

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developin…

Market Cap: $1.40Bwww.intelliatx.com

Price

No data yet.

Social Signal Score

41
5d
—
30d
41
5 mentions
—
60d
38
7 mentions
—
90d
43
9 mentions
—
news: 9

Analyst Ratings

39 analysts
Buyconsensus
Strong Buy 0Buy 29Hold 7Sell 3Strong Sell 0
Avg price target$18.17+81.7%
Low $8Median $18.5High $30
Current Consensus

Revenue

$7.16M+27.30%
$-1.92M$8.37M$18.65M$28.93M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.98
$-4.12–$-3.80
17 analysts
FY2026
$-3.33
$-3.66–$-2.97
13 analysts
FY2027
$-2.76
$-3.86–$1.09
13 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
John Leonard
Sector
Healthcare
Industry
Biotechnology
Employees
377
Beta
1.82
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
-2.55
www.intelliatx.com